DeepMed Research

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

eVusheld Assessment reaL wORld Effectiveness at UPMC

Completed

Conditions: SARS-CoV-2, COVID-19

Interventions: Drug: EVUSHELD

First Posted Date: 2022-12-28

Last Posted Date: 2024-11-11

Lead Sponsor: AstraZeneca

Target Recruit Count: 4232

Registration Number: NCT05667116

Locations: 🇺🇸
Research Site, Pittsburgh, Pennsylvania, United States

Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

Active, not recruiting

Conditions: Previously Untreated Chronic Lymphocytic Leukaemia (Including Small Lymphocytic Lymphoma)

First Posted Date: 2022-12-27

Last Posted Date: 2025-04-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 67

Registration Number: NCT05665374

Locations: 🇯🇵
Research Site, Yamanashi, Japan

eVusheld Assessment reaL wORld Effectiveness in the VA Health System

Completed

Conditions: SARS-CoV-2, COVID-19

Interventions: Drug: Evusheld

First Posted Date: 2022-12-23

Last Posted Date: 2024-03-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 5814

Registration Number: NCT05663957

Locations: 🇺🇸
Research Site, Salt Lake City, Utah, United States

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

Recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Non-GLP-1 RA based glucose lowering drugs
Drug: Exenatide

First Posted Date: 2022-12-23

Last Posted Date: 2025-05-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 24000

Registration Number: NCT05663515

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy and Chronic Obstructive Pulmonary Disease Participants, to Assess the Relative Oral Bioavailability Between Two Formulations, and the Food Effect on the PK of AZD6793 Compared to Fasting State.

Phase 1

Completed

Conditions: Inflammatory Diseases

Interventions: Drug: AZD6793
Drug: Placebo

First Posted Date: 2022-12-22

Last Posted Date: 2024-12-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 93

Registration Number: NCT05662033

Locations: 🇬🇧
Research Site, Wythenshawe, United Kingdom

Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study

Phase 2

Completed

Conditions: COVID-19, SARS-CoV-2

Interventions: Biological: AZD7442 - EVUSHELD™ (Sub-study)
Biological: AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
Biological: AZD5156 (Parent study Sentinel Safety Cohort)
Biological: Placebo (Parent study Sentinel Safety Cohort)
Biological: EVUSHELD™ (Parent study Main Cohort)
Biological: Placebo (Parent study Main Cohort)
Biological: AZD3152 (Sub-study)
Biological: AZD3152 (Parent study Main Cohort)

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 3882

Registration Number: NCT05648110

Locations: 🇻🇳
Research Site, Hochiminh city, Vietnam

First in Human Study of AZD9592 in Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumours
Carcinoma Non-small Cell Lung
Head and Neck Neoplasms
Colorectal Neoplasms

Interventions: Drug: AZD9592
Drug: 5-Fluorouracil (5-FU)
Drug: Osimertinib
Drug: Leucovorin
Drug: Bevacizumab

First Posted Date: 2022-12-12

Last Posted Date: 2025-05-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 228

Registration Number: NCT05647122

Locations: 🇨🇳
Research Site, Taoyuan, Taiwan

A Study to Assess the Effect of AZD5055 on the Pharmacokinetics (PK) of Nintedanib in Healthy Participants.

Phase 1

Terminated

Conditions: Healthy Subjects

Interventions: Drug: Nintedanib
Drug: AZD5055

First Posted Date: 2022-12-09

Last Posted Date: 2024-02-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT05644600

Locations: 🇬🇧
Research Site, Glendale, United Kingdom

Retention Rate of Acalabrutinib in a Non-interventional Setting

Recruiting

Conditions: Chronic Lymphocytic Leukaemia (CLL)

First Posted Date: 2022-12-09

Last Posted Date: 2025-04-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 200

Registration Number: NCT05645172

Locations: 🇩🇪
Research Site, Zittau, Germany

A Study in Participants With Non-cirrhotic NASH With Fibrosis

Phase 2

Completed

Conditions: Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Interventions: Drug: AZD4831
Other: Placebo

First Posted Date: 2022-12-06

Last Posted Date: 2024-04-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 122

Registration Number: NCT05638737

Locations: 🇸🇪
Research Site, Uppsala, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy